Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.90), $0.04 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $0 versus the consensus estimate of $197.1 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.